Modulation of Immune Cells as a Therapy for Cutaneous Lupus Erythematosus
Cargando...
Archivos
Fecha
2022-09
Profesor/a Guía
Facultad/escuela
Idioma
en
Título de la revista
ISSN de la revista
Título del volumen
Editor
MDPI
Nombre de Curso
Licencia CC
CC BY 4.0 DEED
Attribution 4.0 International
Licencia CC
https://creativecommons.org/licenses/by/4.0/
Resumen
Cutaneous lupus erythematosus (CLE) is an autoimmune disorder like systemic lupus erythematosus (SLE). Both SLE and CLE characterize autoantibody secretion and immune cell recruitment. In particular, CLE can be divided into three more frequent types, varying in the severity of the skin lesions they present. The role of type I IFN was shown to be one of the leading causes of the development of this pathology in the skin. Different treatments have been developed and tested against these different variants of CLE to decrease the increasing levels of CLE in humans. In this article, a literature revision discussing the similarities between SLE and CLE is carried out. In addition, new advances in understanding the development of CLE and the leading treatments being evaluated in animal models and clinical trials are reviewed.
Notas
Indexación: Scopus.
Palabras clave
Cutaneous lupus erythematosus, Immune cells, Systemic lupus erythematosus, Treatments
Citación
International Journal of Molecular Sciences, Open Access, Volume 23, Issue 18 September 2022, Article number 10706
DOI
10.3390/ijms231810706